celecoxib has been researched along with luteolin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, QH; Knaus, EE; Rao, PN | 1 |
| Jeon, YW; Suh, YJ | 1 |
| Ahn, YE; Choi, HJ; Chung, WS; Jeon, YW; Suh, YJ | 1 |
| Ahmed, S; Fathi, N; Fratantonio, D; Hasan, MM; Khan, H; Rastrelli, L; Sharifi, S; Ullah, H | 1 |
1 review(s) available for celecoxib and luteolin
| Article | Year |
|---|---|
Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Celecoxib; Cyclophosphamide; Doxorubicin; Female; Humans; Luteolin | 2019 |
3 other study(ies) available for celecoxib and luteolin
| Article | Year |
|---|---|
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Topics: Administration, Oral; Alkynes; Analgesics; Animals; Arachidonate 15-Lipoxygenase; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Lipoxygenase Inhibitors; Mice; Models, Molecular; Pain Measurement; Rats; Structure-Activity Relationship | 2006 |
Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells.
Topics: Analysis of Variance; Antioxidants; Apoptosis; Celecoxib; Cell Proliferation; Cell Survival; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Humans; Luteolin; MCF-7 Cells; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Sulfonamides | 2013 |
Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Celecoxib; Cell Proliferation; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Luteolin; MAP Kinase Signaling System; MCF-7 Cells; Mice; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |